Study guide
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis
Certified Wound Specialist Physician CWSP
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the CWSP Exam
2 Chapter 1: Integumentary Anatomy & Wound Healing Biology
1.1 Skin Anatomy, Microstructure & Epidermal-Dermal Barrier Function 1.2 Acute vs Chronic Wound Healing Phases & Cellular Kinetics 1.3 Extracellular Matrix Composition, Collagen Architecture & MMP Regulation
3 Chapter 2: Musculoskeletal & Neurologic Anatomy
2.1 Musculoskeletal Anatomy of the Leg & Foot 2.2 Neuroanatomy & Nerve Physiology for Wound Care
4 Chapter 3: Cell Signaling, Biofilm & Barriers to Healing
3.1 Growth Factors, Cytokines & Angiogenic Pathways 3.2 Biofilm Microbiology, Quorum Sensing & Phenotypic Resistance 3.3 Cellular Senescence, Hypoxia & Inflammatory Arrest 3.4 Metabolic, Steroid & Nutritional Impairments in Wound Healing
5 Chapter 4: Patient Evaluation & Vascular Diagnostics
4.1 Comprehensive Patient & Periwound Physical Examination 4.2 Noninvasive Macrovascular Hemodynamics: ABI, TBI & Segmental Pressures 4.3 Microvascular Perfusion Diagnostics: TcPO2, SPP & Near-Infrared Spectroscopy 4.4 Diagnostic Angiography, Duplex Ultrasonography & Angiosome Concepts
6 Chapter 5: Pain, Risk, Functional & Nutrition Assessment
5.1 Wound Pain Assessment 5.2 Risk Assessment Tools & Risk Stratification 5.3 Functional & Cognitive Assessment 5.4 Nutrition Screening & Assessment
7 Chapter 6: Imaging, Biopsy, Atypical Wounds & Neuropathy
6.1 Musculoskeletal Imaging for Osteomyelitis & Deep Space Infections 6.2 Diagnostic Tissue Biopsy, Culture Techniques & Quantitative Microbiology 6.3 Diagnostic Differential of Atypical & Malignant Ulcerations 6.4 Comprehensive Diabetic Peripheral Neuropathy & Biomechanical Assessment
8 Chapter 7: Wound Bed Preparation, Debridement, Dressings & Topical Agents
7.1 TIME Principle & Wound Bed Preparation Framework 7.2 Surgical, Sharp, Enzymatic, Autolytic & Biosurgical Debridement Modalities 7.3 Advanced Wound Dressings, Exudate Control & Moisture Balance 7.4 Topical Agents: Antiseptics, Antibiotics & Active Topicals
9 Chapter 8: Cellular & Tissue-Based Products, NPWT & Hyperbaric Oxygen
8.1 Cellular, Acellular & Matrix-Like Advanced Biologics (CTPs) 8.2 Negative Pressure Wound Therapy (NPWT) & Instillation Protocols 8.3 Hyperbaric Oxygen Therapy (HBOT): Mechanisms, Indications & Safety
10 Chapter 9: Biophysical Technologies: Electrical Stimulation & Ultrasound
9.1 Electrical Stimulation for Wound Healing 9.2 Therapeutic Ultrasound in Wound Care
11 Chapter 10: Revascularization, Antimicrobial Stewardship & Offloading
10.1 Revascularization for Limb Salvage 10.2 Systemic Antimicrobial Stewardship & Deep Infection Management 10.3 Mechanical Offloading, Pressure Redistribution & Total Contact Casting
12 Chapter 11: Surgical Closure & Healing Complications
11.1 Surgical Closure, Skin Grafts, Flaps & Amputation Levels 11.2 Managing Complications: Bleeding, Allergy, Adverse Events & Scarring
13 Chapter 12: Nutrition Therapy & Case Review
12.1 Nutrition Therapy for Wound Healing 12.2 Case Review: Synthesizing Data, Outliers & Prognosis
14 Chapter 13: Diabetic & Ischemic Lower-Extremity Wounds
13.1 Diabetic Foot Ulcers: Pathophysiology, Staging & Limb Salvage 13.2 Peripheral Arterial Disease & Ischemic Extremity Ulcerations 13.3 Mixed Arterial-Venous Disease & Complex Diagnostic Dilemmas
15 Chapter 14: Venous Disease, Pressure Injuries, Lymphedema & Edema
14.1 Venous Leg Ulcers, Chronic Venous Insufficiency & Compression 14.2 Pressure Injuries: NPIAP Staging, DTPI & Prevention 14.3 Lymphedema, Phlebolymphedema & Complete Decongestive Therapy 14.4 Edema: Systemic vs. Local Causes
16 Chapter 15: Inflammatory, Calcific, Medication-Induced & Dermatologic Wounds
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis 15.2 Calciphylaxis & Radiation Tissue Injury 15.3 Medication-Induced & Hematologic Atypical Wounds 15.4 Dermatologic Conditions That Cause or Complicate Wounds
17 Chapter 16: Traumatic Wounds, Burns & Frostbite
16.1 Traumatic Wounds: Lacerations, Bites, Degloving & Open Fractures 16.2 Thermal Burns & Frostbite
18 Chapter 17: Surgical, Infectious & Pediatric Wounds
17.1 Surgical Wounds, Surgical Site Infection & Dehiscence 17.2 Infectious Causes of Wounds: Necrotizing, Mycobacterial, Fungal & Other Infections 17.3 Pediatric Wound Care
19 Chapter 18: Reimbursement, Regulation & Documentation
18.1 CPT Coding, Modifiers & Documentation for Debridement and Biologics 18.2 Regulatory Compliance, CMS Quality Programs & Hospital-Acquired Conditions 18.3 Documentation, Legal Concepts & Confidentiality
20 Chapter 19: Ethics, Adherence, Epidemiology & Evidence-Based Practice
19.1 Clinical Ethics, Informed Consent & Palliative Wound Management 19.2 Patient Adherence & Psychosocial Care 19.3 Epidemiology of Chronic Wounds 19.4 Research Literacy, Evidence-Based Medicine & Quality Improvement
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis
Key Takeaways Explain This Topic AI
Pyoderma Gangrenosum (PG) is a sterile neutrophilic dermatosis presenting as an exquisitely painful lesion with violaceous, undermined, gunmetal borders and cribriform scarring; aggressive sharp debridement should be avoided because of pathergy, where trauma can trigger rapid ulcer expansion.
The 2018 Delphi consensus requires one major criterion (ulcer-edge biopsy showing a neutrophilic infiltrate) plus at least 4 of 8 minor criteria, and a PARACELSUS score of 10 or more makes pyoderma gangrenosum likely; about half of cases are associated with inflammatory bowel disease, inflammatory arthritis, or hematologic disorders.
First-line systemic therapy for pyoderma gangrenosum is corticosteroids (commonly prednisone 0.5–1 mg/kg/day, with IV pulses for severe disease) and/or cyclosporine (about 3–5 mg/kg/day); infliximab is the biologic with randomized-trial support, and other biologics are used off-label.
Cutaneous small-vessel vasculitis (leukocytoclastic vasculitis, LCV) is a Type III immune-complex hypersensitivity targeting post-capillary venules and manifesting clinically as non-blanching palpable purpura; early punch biopsy (within 24–48 hours) demonstrates post-capillary venule fibrinoid necrosis, leukocytoclasia (neutrophil karyorrhexis / nuclear dust), and red blood cell extravasation, with direct immunofluorescence (DIF) revealing perivascular IgA and C3 in Henoch-Schönlein purpura versus IgG/IgM/C3 in immune-complex vasculitis.
Connective tissue disease ulcers need disease-specific therapy: rheumatoid vasculitis requires systemic immunosuppression; systemic sclerosis digital ulcers are treated with warming, calcium channel blockers, PDE-5 inhibitors, bosentan, or prostacyclins; thrombotic antiphospholipid syndrome needs warfarin (DOACs are inferior in high-risk triple-positive disease); and necrobiosis lipoidica ulcers are handled gently with topical or intralesional steroids.
Last updated: September 2026
15.1 Autoimmune & Inflammatory Ulcerations: Pyoderma Gangrenosum & Vasculitis
Core Clinical Principle: Autoimmune and inflammatory ulcers represent cutaneous manifestations of dysregulated host immunity rather than primary infectious or purely macrovascular processes. Accurate recognition is vital because conventional wound management paradigms—specifically aggressive sharp surgical debridement—can induce catastrophic, rapid tissue destruction through pathergy. Definitive wound healing requires aggressive systemic immunosuppression, targeted biologic pathway inhibition, and precise microvascular vasodilation.
Non-healing lower extremity wounds that fail to respond to standard arterial revascularization, venous compression, or pressure offloading frequently represent underlying autoimmune, inflammatory, or connective tissue disorders. Clinicians preparing for board certification must distinguish the violaceous, undermined borders of sterile neutrophilic dermatoses from bacterial pyodermas, identify post-capillary venule leukocytoclastic vasculitis, and tailor pharmacotherapy to the unique microvascular pathologies of systemic sclerosis, rheumatoid vasculitis, and antiphospholipid syndrome.
Pyoderma Gangrenosum (PG): Pathobiology, Clinical Phenotype & Pathergy
Pyoderma Gangrenosum (PG) is a rare, non-infectious, sterile inflammatory ulcerative condition classified under the spectrum of neutrophilic dermatoses (which also includes Sweet syndrome and subcorneal pustular dermatosis). Despite its historical misnomer, PG is neither an infectious bacterial pyoderma nor a gangrenous necrosis caused by primary arterial occlusion; rather, it is driven by dysregulated innate immunity and aberrant neutrophil recruitment. +-------------------------------------------------------------------------------------------------+
- | PATHOPHYSIOLOGICAL CASCADE OF PYODERMA GANGRENOSUM |
- +-------------------------------------------------------------------------------------------------+
- | 1. INNATE IMMUNE HYPER-REACTIVITY & INFLAMMASOME ACTIVATION |
- | • Overactivation of the NLRP3 inflammasome and upregulated caspase-1 activity |
- | • Massive cleavage and secretion of active interleukin-1β (IL-1β), IL-6, and TNF-alpha |
- | • Marked overexpression of neutrophil chemokines: CXCL1, CXCL2, CXCL8 (IL-8) |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 2. ABERRANT NEUTROPHILIC MARGINATION & EXTRAVASATION |
- | • Neutrophils exhibit intrinsic resistance to physiological apoptosis and hyperchemotaxis |
- | • Uncontrolled diapedesis into dermal and subcutaneous architectures |
- | • Release of Human Neutrophil Elastase (HNE), Cathepsin G, and gelatinases (MMP-8, MMP-9) |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 3. STERILE DERMAL ABSCESS & TISSUE LIQUEFACTION |
- | • Enzymatic degradation of dermal extracellular matrix collagen and elastic fibers |
- | • Subepidermal microabscesses coalesce -> Bulla/pustule roof necrotic detachment |
- | • Secondary ischemia due to reactive microthrombi and endothelial swelling |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | 4. CLINICAL ULCERATION & THE PATHERGY PHENOMENON |
- | • Exquisitely painful, rapidly advancing ulceration with undermined, violaceous borders |
- | • Mechanical microtrauma (scalpel debridement, punch biopsy, venipuncture, minor bump) |
- | --> Triggers exponential neutrophil recruitment ('Pathergy') -> Massive ulcer expansion |
- +-------------------------------------------------------------------------------------------------+
- Clinical Presentation & Morphologic Stages
The clinical presentation of classic ulcerative PG evolves through discrete stages:
Inception: Lesions begin insidiously as a small, tender erythematous nodule, an inflammatory pustule, or a hemorrhagic bulla, frequently occurring on the pretibial lower extremity, trunk, or peristomal skin following an ostomy procedure ( peristomal PG ).
Centrifugal Ulcerative Breakdown: Within 24 to 72 hours, the pustule undergoes central sterile liquefactive necrosis and breaks down into a rapidly spreading ulceration. The pain is severe, constant, and characteristically described as disproportionate to the physical dimensions of the wound.
Classic Border Morphology: The ulcer margins have a characteristic appearance: violaceous (blue-purple or gunmetal-colored), raised, edematous, and prominently undermined borders. Advancing inflammatory borders can expand centrifugally by several centimeters in a single week.
Wound Bed & Healing Base: The ulcer base is covered with sterile, purulent exudate, necrotic yellow-gray slough, and exuberant, non-viable, violaceous granulation tissue. Upon successful immunosuppression and healing, PG lesions resolve with a distinctive, thin, atrophic, sieve-like scar termed cribriform scarring .
The Pathergy Phenomenon: Strict Contraindication to Surgical Debridement
Pathergy is defined as the development of a new ulcer or the catastrophic enlargement of a pre-existing lesion in response to minor local cutaneous trauma or surgical intervention. Pathergy occurs in 25% to 50% of patients with PG . ==================================================================================
- CRITICAL CLINICAL WARNING: SHARP SURGICAL DEBRIDEMENT CONTRAINDICATION
- ==================================================================================
- In Pyoderma Gangrenosum, SHARP SURGICAL EXCISIONAL DEBRIDEMENT IS STRICTLY
CONTRAINDICATED!
- Attempting scalpel debridement, curettage, or aggressive wound margin revision
- triggers explosive pathergic amplification: trauma mechanically activates dermal
- fibroblasts and keratinocytes to release massive pulses of CXCL8/IL-8, drawing
- millions of hyper-reactive neutrophils to the margins. Within 24 to 48 hours of
- a surgical debridement, an ulcer can quadruple in surface area, transforming a
2-cm stable wound into a 10-cm necrotic catastrophe.
- Wound cleansing must be strictly atraumatic: gentle saline irrigation, non-adherent
- contact layers, autolytic/enzymatic preparations, and immediate systemic
immunosuppression.
- ==================================================================================
- Systemic Comorbidities & Disease Associations
About half of pyoderma gangrenosum cases are associated with an underlying systemic disease :
Inflammatory Bowel Disease (IBD): Present in 30% to 50% of all PG cases. Ulcerative colitis is more frequently associated than Crohn's disease. PG ulcer activity does not always parallel bowel disease activity; an active PG flare may occur during endoscopic gastrointestinal remission or vice versa.
Rheumatoid Arthritis (RA) & Seronegative Spondyloarthropathies: Present in 15% to 20% of cases, particularly in patients with severe, erosive, seropositive polyarthritis, ankylosing spondylitis, or psoriatic arthritis.
Hematologic Malignancies & Dysplasias: Present in 10% to 15% of cases. The most critical association is Myelodysplastic Syndrome (MDS) (often characterized by trisomy 8), followed by monoclonal gammopathy of undetermined significance (MGUS; especially IgA gammopathy), acute myeloid leukemia (AML), and polycythemia vera. In hematologic-associated PG, lesions frequently present with a bullous or superficial vegetative morphotype on the upper extremities or face.
Autoinflammatory Syndromes: Rare monogenic disorders including PAPA syndrome (Pyogenic arthritis, Pyoderma gangrenosum, and Acne; caused by PSTPIP1 mutations) and PASH syndrome (Pyoderma gangrenosum, Acne, and Suppurative hidradenitis).
Diagnostic Criteria: Delphi Consensus & The PARACELSUS Score
Historically, Pyoderma Gangrenosum was an exclusionary diagnosis without standardized rubrics, leading to misdiagnosis in up to 30% of clinical presentations. Two internationally validated diagnostic frameworks have established rigorous objective parameters:
1. The Delphi Consensus Criteria (Maverakis et al., JAMA Dermatology, 2018)
To diagnose ulcerative pyoderma gangrenosum, a patient must meet the single major criterion and at least 4 of the 8 minor criteria : DELPHI CONSENSUS DIAGNOSTIC CRITERIA FOR ULCERATIVE PYODERMA GANGRENOSUM
==================================================================================
MAJOR CRITERION (REQUIRED):
• Biopsy of the ulcer edge demonstrating a neutrophilic infiltrate.
MINOR CRITERIA (AT LEAST 4 OF 8):
1. Exclusion of infection (histology with special stains and tissue cultures).
2. Pathergy (ulcer occurring at a site of trauma).
3. Personal history of inflammatory bowel disease or inflammatory arthritis.
4. History of a papule, pustule, or vesicle that ulcerated within 4 days.
5. Peripheral erythema, undermining border, and tenderness at the ulcer site.
6. Multiple ulcerations, at least one on the anterior lower leg.
7. Cribriform or "wrinkled paper" scars at healed ulcer sites.
8. Decreased ulcer size within 1 month of starting immunosuppressive medication.
- ==================================================================================
- 2. The PARACELSUS Score (Jockenhöfer et al., British Journal of Dermatology, 2019)
The PARACELSUS score is a weighted scoring system designed specifically for lower extremity ulcers, evaluating clinical progression, morphology, systemic comorbidities, and therapeutic response:
Criterion Category Specific Clinical Parameter Assigned Points
Major Criteria ; (3 points each) P - Progressing disease (rapid expansion within days); A - Assessment of alternative etiologies excluded (venous, arterial, infection, neoplasm); R - Reddened/violaceous wound border (erythematous/livid margin with undermining) 3 points ; 3 points ; 3 points
Minor Criteria ; (2 points each) A - Amelioration by immunosuppressive therapy (steroids/cyclosporine induces rapid stabilization); C - Characteristic irregular ulcer shape (serpiginous, bizarre contour); E - Extreme pain (Visual Analog Scale pain score > 4/10 or disproportional to size); L - Localization at site of trauma (pathergic trigger) 2 points ; 2 points ; 2 points ; 2 points
Additional Criteria ; (1 point each) S - Suppurative inflammation on histopathology; U - Undermined wound edge (subdermal excavation beyond visible epidermal margin); S - Systemic disease associated (IBD, rheumatoid arthritis, monoclonal gammopathy, MDS) 1 point ; 1 point ; 1 point INTERPRETATION OF THE PARACELSUS SCORE:
• A total score of 10 points or more indicates that pyoderma gangrenosum is likely.
• Lower scores make PG less likely; continue evaluating alternative diagnoses.
Histopathology & Diagnostic Biopsy Technique
While histopathology does not reveal a pathognomonic single biomarker for PG, a biopsy is mandatory to satisfy the Delphi major criterion and exclude alternative etiologies (squamous cell carcinoma, deep fungal infection, mycobacterial infection, vasculitis, and calciphylaxis).
Biopsy Technique: Biopsy must be performed at the advancing, active, violaceous border , spanning both intact skin and the ulcer edge, extending through the full-thickness dermis into the superficial subcutaneous fat. Because punch biopsy induces minor mechanical trauma, it carries a small risk of pathergy; however, this risk is managed by concurrently initiating systemic immunosuppression if the clinical suspicion is elevated.
Histopathologic Hallmarks: The characteristic finding is an intense, sheet-like, sterile neutrophilic infiltrate (dermal microabscesses) occupying the reticular dermis and tracking into the subcutis. Extensive tissue necrosis, collagenolysis, and leukocytoclasia (neutrophilic karyorrhexis with nuclear debris / 'nuclear dust') are present.
Absence of Primary Vasculitis: Although secondary vascular thrombosis and reactive intramural neutrophil invasion occur in areas of dense necrosis, PG does not demonstrate primary necrotizing vasculitis of muscular arteries or post-capillary venules. The internal elastic lamina of medium vessels remains structurally intact.
Mandatory Microbiological Rule-Out: Every biopsy specimen must be bisected: one half sent for formalin-fixed paraffin-embedded histopathology, and the other half minced and sent fresh for aerobic, anaerobic, mycobacterial (AFB), and deep fungal cultures ( Sporothrix schenckii , Blastomyces , Histoplasma , Coccidioides ).
Medical Management of Pyoderma Gangrenosum
Because PG is an autoinflammatory disorder, systemic immunosuppression is the absolute cornerstone of medical intervention. Treatment is stratified into first-line systemic therapies and second-line targeted biologics: +-------------------------------------------------------------------------------------------------+
- | PHARMACOTHERAPEUTIC ALGORITHM FOR PYODERMA GANGRENOSUM |
- +-------------------------------------------------------------------------------------------------+
- | FIRST-LINE SYSTEMIC IMMUNOSUPPRESSION |
- | • Systemic Corticosteroids: Oral Prednisone commonly 0.5-1 mg/kg/day (rapid anti-inflammatory) |
- | OR IV Pulse Methylprednisolone (1.0 g/day for 3 consecutive days for fulminant cases) |
- | • Calcineurin Inhibitors: Oral Cyclosporine A (3-5 mg/kg/day; target trough 150-250 ng/mL) |
- | --> Cyclosporine provides steroid-sparing immunosuppression; monitor renal function & BP |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼ (Inadequate response after 2 to 4 weeks)
- +-------------------------------------------------------------------------------------------------+
- | SECOND-LINE TARGETED BIOLOGIC THERAPY |
- | • Anti-TNF-Alpha Monoclonal Antibodies: |
- | - Infliximab (5 mg/kg IV at weeks 0, 2, 6, then q8w) -- Only biologic proven in RCTs! |
- | - Adalimumab (160 mg subQ week 0, 80 mg week 2, then 40 mg weekly) |
- | • Interleukin Inhibitors: |
- | - Ustekinumab (IL-12/23 p40 inhibitor; 90 mg subQ at weeks 0, 4, then q8-12w) |
- | - Anakinra (recombinant IL-1 receptor antagonist; 100 mg subQ daily) |
- +-------------------------------------------------------------------------------------------------+
- │
- ▼
- +-------------------------------------------------------------------------------------------------+
- | ADJUNCTIVE TOPICAL & LOCAL WOUND PROTOCOLS |
- | • Mild / Peristomal PG: Superpotent topical steroids (Clobetasol 0.05% ointment) or |
- | topical calcineurin inhibitors (Tacrolimus 0.1% ointment) under non-adherent silicone |
- | • Atraumatic dressings: Hydrofiber, polyurethane foam, calcium alginate (avoid adhesives) |
- | • ZERO sharp debridement; gentle enzymatic / autolytic cleansing only |
- +-------------------------------------------------------------------------------------------------+
- Clinical Pharmacotherapy Pearls
Infliximab Evidence: Infliximab is the only biologic therapy evaluated in a randomized, double-blind, placebo-controlled trial for PG (Brooklyn et al., Gut , 2006). A single 5 mg/kg infusion achieved clinical improvement in 46% of patients at 2 weeks (vs 6% on placebo), with 69% demonstrating clinical response after subsequent open-label infusions.
Cyclosporine Monitoring: When utilizing cyclosporine A (3–5 mg/kg/day), baseline serum creatinine, BUN, blood pressure, and magnesium must be monitored weekly for the first month. Cyclosporine induces renal vasoconstriction, risking acute kidney injury and systemic hypertension.
Cutaneous Small-Vessel Vasculitis (Leukocytoclastic Vasculitis - LCV)
Cutaneous Small-Vessel Vasculitis (CSVV) , historically termed leukocytoclastic vasculitis (LCV) , is an immune-complex-mediated inflammatory destruction of the cutaneous microcirculation, with an exclusive affinity for dermal post-capillary venules .
Pathophysiology & Etiology
Type III Hypersensitivity: Circulating antigen-antibody immune complexes deposit in the walls of post-capillary venules. Deposition triggers the classical complement cascade, generating C3a and C5a anaphylatoxins that recruit and activate polymorphonuclear neutrophils.
Triggers: Idiopathic in 45% to 50% of cases. Recognized precipitants include:
Infections (15–20%): Group A beta-hemolytic Streptococcus , viral hepatitis (HCV, HBV), Epstein-Barr virus.
Medications (10–15%): Beta-lactam antibiotics, sulfonamides, nonsteroidal anti-inflammatory drugs (NSAIDs), allopurinol, propylthiouracil, thiazide diuretics.
Autoimmune / Connective Tissue Disease (10–15%): Systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome.
Malignancy (2–5%): Lymphoma, multiple myeloma.
Clinical Hallmarks: Palpable Purpura & Diascopy
Palpable Purpura: The clinical hallmark of LCV is palpable purpura —non-blanching, raised, erythematous to violaceous macules and papules that range from 2 mm to 1 cm in diameter. Lesions exhibit a symmetrical distribution, with heavy predilection for dependent, gravity-stressed anatomical zones (bilateral lower extremities, ankles, and buttocks).
Diascopy Technique: Diascopy is performed by pressing a clear glass or plastic microscope slide firmly against the lesion:
In erythema (e.g., cellulitis, stasis dermatitis), the red color is due to intravascular capillary dilation; external compression expels the blood, causing the lesion to blanch (turn white) .
In vasculitic purpura, red blood cells have physically extravasated through necrotic vessel walls into the dermis; external compression cannot move extravascular blood, so the lesion does not blanch .
Ulcerative Progression: In severe or necrotizing LCV, confluent microvascular thrombosis produces retiform purpura (stellate, branching purpuric patterns), hemorrhagic bullae, and superficial, targetoid, punched-out skin ulcerations.
Histopathology & Direct Immunofluorescence (DIF)
Light Microscopy (Hematoxylin & Eosin): Optimal biopsy timing is within 24 to 48 hours of lesion eruption . Biopsying older lesions yields non-specific lymphocytic or granulomatous inflammation. The characteristic histopathological triad includes:
Transmural Post-Capillary Venule Infiltration: Neutrophils infiltrating and destroying the venular wall.
Fibrinoid Necrosis: Smudgy, eosinophilic deposition of fibrin within and around vessel walls.
Leukocytoclasia: Marked neutrophil fragmentation, karyorrhexis, and chromatin breakdown producing abundant nuclear dust .
Extravasated Erythrocytes: Prominent red blood cells spilled into the surrounding perivascular dermis.
Direct Immunofluorescence (DIF): Mandatory to distinguish systemic vasculitic subtypes:
Henoch-Schönlein Purpura (IgA Vasculitis): Demonstrates granular, continuous perivascular IgA and C3 deposition within the post-capillary venule walls. Frequently accompanied by gastrointestinal purpura (colic, bleeding), glomerulonephritis (hematuria, proteinuria), and migratory arthralgias.
Non-IgA Immune-Complex CSVV: Demonstrates predominant perivascular IgG, IgM, and C3 deposition .
Connective Tissue Disease Wounds: Clinical Entities & Targeted Protocols
Disease Entity Primary Microvascular Pathology Clinical Ulcer Morphotype & Location Distinctive Cutaneous Features Treatment Protocols & Clinical Traps
Rheumatoid Vasculitis (RV) Immune-complex necrotizing vasculitis of small- to medium-sized muscular arteries Punched-out, deep, painful, necrotic ulcers over the malleoli, Achilles tendon, and pretibial calf ; digital gangrene High rheumatoid factor (RF) titers, elevated anti-CCP antibodies, cutaneous rheumatoid nodules, nail fold infarcts (Bywaters' lesions) Requires aggressive escalation of systemic immunosuppression: High-dose corticosteroids PLUS Rituximab (anti-CD20) or Cyclophosphamide . Simple local wound dressings fail without systemic control.
Systemic Sclerosis (Scleroderma / CREST) Non-inflammatory, obliterative, proliferative microvascular endarteropathy; severe vasospasm Digital tip / pulp ulcerations , exquisite pain; ulcerations over PIP/DIP joints and bony prominences Raynaud's phenomenon , sclerodactyly, digital pitting scars, calcinosis cutis , telangiectasias First-line: Environmental warming, Dihydropyridine Calcium Channel Blockers (e.g., Nifedipine 30–60 mg daily).; Advanced: Phosphodiesterase-5 (PDE-5) inhibitors ( Sildenafil ), Endothelin receptor antagonists ( Bosentan ), IV Prostacyclin analogs ( Iloprost ).; Caution: Nonselective beta-blockers are traditionally avoided in severe Raynaud's phenomenon because they may worsen vasospasm, although controlled studies have not consistently shown harm; avoid other vasoconstrictors such as nicotine and sympathomimetics.
Antiphospholipid Syndrome (APS) Non-inflammatory thrombotic microangiopathy; recurrent venous/arterial microthrombosis Painful purpuric papules evolving into retiform purpura , stellate necrotic ulcers, digital gangrene Livedo reticularis (violaceous net-like pattern), anetoderma, splinter hemorrhages; recurrent miscarriages, DVT/PE Driven by lupus anticoagulant, anticardiolipin antibodies, anti-beta-2-glycoprotein I.; Mandatory Therapy: Lifelong systemic anticoagulation with therapeutic Warfarin (target INR 2.0–3.0) . DOACs are inferior in triple-positive high-risk APS! Debridement without systemic anticoagulation fails.
Necrobiosis Lipoidica Diabeticorum (NLD) Collagen degeneration (necrobiosis), microangiopathy, and palisading granulomatous dermatitis Atrophic, sluggish, shallow ulcers occurring secondarily within pre-existing atrophic plaques after minor trauma Pretibial bilateral shiny, waxy, yellow-brown plaques with prominent overlying arborizing telangiectasias and violaceous active borders Ulceration occurs in ~30% of plaques following trivial trauma.; First-line Therapy: High-potency topical corticosteroids (Clobetasol 0.05%) applied to active violaceous borders (NOT into atrophic yellow center) or intralesional triamcinolone (5–10 mg/mL) injected into active margins. Pentoxifylline, topical tacrolimus.; Avoid aggressive debridement ; the atrophic, poorly vascularized dermis heals poorly, and trauma can enlarge ulcers.
Loading diagram... Diagnostic and Therapeutic Algorithm for Suspected Pyoderma Gangrenosum & Inflammatory Ulcerations